Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

At this time, Beam Therapeutics has an average Growth Score of C, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade ... with -$0.30 a year ...

The participants were evenly distributed across cohorts and received either 15, 30 or 60 ... and grade 1 infusion-related reactions, which didn’t require treatment, Beam said.

Under the terms of the order, SatixFy will be supplying Prime2 Space-Grade chips and software over ... chip is a game-changer for multi-beam Low Earth Orbit (LEO) or Geostationary Earth Orbit ...